P3.02a-021 Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC

Xiangchan Hong; Haiying Wu

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P3.02a-021 Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC

【24h】

P3.02a-021 Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC

机译：P3.02A-021临床益处临床益处持续的肝肾疗法治疗中国晚期ALK -Rearanged NSCLC患者的初期疾病进展

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第1期|共1页
作者
Xiangchan Hong; Haiying Wu;
展开▼
作者单位

Department of Oncology Sun Yat-Sen University Cancer Center/China;

Sun Yat-Sen University Cancer Center;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P3.02a-021 Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC [J] . Xiangchan Hong, Haiying Wu Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P3.02A-021临床益处临床益处持续的肝肾疗法治疗中国晚期ALK -Rearanged NSCLC患者的初期疾病进展
2. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. [J] . C Leduc, B Besse Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第10期

机译：在晚期ALK阳性NSCLC患者中，用crizotinib继续ALK抑制的临床益处超出了疾病的初始进展。
3. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC [J] . OuS.-H.I., J?nneP.A., BartlettC.H., Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第2期

机译：克唑替尼持续ALK抑制超过晚期ALK阳性NSCLC患者初始疾病进展的临床益处
4. Delta-Radiomics Signature For Prediction Of Survival In Advanced Nsclc Patients Treated With Immunotherapy [C] . B. Farina, A. D. Ramos Guerra, C. Palacios Miras, IEEE International Symposium on Biomedical Imaging . 2021

机译：用于预测免疫疗法治疗的高级NSCLC患者存活的三角洲 - 辐射瘤
5. Yoga as an adjunctive therapy for Crohn's disease: A review of the effects of exercise and stress reduction on the quality of life and disease progression in Crohn's disease patients. [D] . Zuckerman, Julie. 2012

机译：瑜伽作为克罗恩氏病的辅助疗法：运动和减轻压力对克罗恩氏病患者生活质量和疾病进展的影响综述。
6. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer [O] . Xiangchan Hong, Qi Chen, Lingyu Ding, 2017

机译：中国晚期ALK重排非小细胞肺癌患者初始疾病进展后继续克唑替尼治疗的临床获益
7. P3.02a-021 Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC [O] . Xiangchan Hong, Haiying Wu 2017

机译：P3.02A-021临床益处临床益处持续的肝肾疗法治疗中国晚期ALK -Rearanged NSCLC患者的初期疾病进展

P3.02a-021 Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC

著录项

相似文献

相关主题

期刊订阅